ArticleLeukemia research2020

Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo.

Marquicia R Pierce et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.